Eli Lilly and Company (NYSE:LLY) – Stock analysts at Jefferies Group decreased their FY2017 earnings per share estimates for Eli Lilly and in a report released on Wednesday. Jefferies Group analyst J. Holford now forecasts that the company will post earnings per share of $4.14 for the year, down from their previous forecast of $4.19. Jefferies Group has a “Buy” rating and a $89.00 price target on the stock. Jefferies Group also issued estimates for Eli Lilly and’s FY2020 earnings at $5.83 EPS and FY2021 earnings at $6.77 EPS.

Several other equities research analysts have also issued reports on the stock. BMO Capital Markets reissued an “underperform” rating and issued a $71.00 price target (down previously from $73.00) on shares of Eli Lilly and in a report on Wednesday, September 6th. Piper Jaffray Companies reissued an “overweight” rating and issued a $105.00 price target (up previously from $103.00) on shares of Eli Lilly and in a report on Friday, September 8th. Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price target on the stock in a report on Monday, July 17th. Morgan Stanley reissued a “hold” rating and issued a $86.00 price target on shares of Eli Lilly and in a report on Friday, September 15th. Finally, Credit Suisse Group lowered shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and boosted their price target for the company from $84.23 to $88.00 in a report on Tuesday, October 10th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $88.97.

TRADEMARK VIOLATION NOTICE: This news story was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/20/fy2017-eps-estimates-for-eli-lilly-and-company-lly-cut-by-analyst.html.

Eli Lilly and (NYSE:LLY) traded up 0.59% on Friday, hitting $86.87. 306,288 shares of the stock were exchanged. The company’s 50 day moving average is $84.21 and its 200 day moving average is $82.27. Eli Lilly and has a 1-year low of $64.18 and a 1-year high of $89.09. The stock has a market cap of $91.65 billion, a PE ratio of 37.59 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The company had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. During the same period last year, the firm posted $0.86 EPS. The company’s revenue for the quarter was up 7.8% on a year-over-year basis.

Large investors have recently made changes to their positions in the business. Acrospire Investment Management LLC raised its holdings in Eli Lilly and by 16.7% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares during the last quarter. MPS Loria Financial Planners LLC bought a new stake in Eli Lilly and during the 2nd quarter worth about $128,000. San Francisco Sentry Investment Group CA bought a new stake in Eli Lilly and during the 2nd quarter worth about $129,000. Heritage Trust Co bought a new stake in Eli Lilly and during the 1st quarter worth about $135,000. Finally, Point72 Asia Hong Kong Ltd raised its holdings in Eli Lilly and by 237.4% during the 1st quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock worth $148,000 after purchasing an additional 1,239 shares during the last quarter. 75.53% of the stock is owned by hedge funds and other institutional investors.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 180,000 shares of the business’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $81.06, for a total transaction of $14,590,800.00. Following the completion of the sale, the insider now directly owns 123,865,804 shares of the company’s stock, valued at approximately $10,040,562,072.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 990,000 shares of company stock valued at $82,949,650 over the last three months. Company insiders own 0.20% of the company’s stock.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be issued a dividend of $0.52 per share. The ex-dividend date is Tuesday, November 14th. This represents a $2.08 annualized dividend and a yield of 2.41%. Eli Lilly and’s dividend payout ratio is currently 90.04%.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Earnings History and Estimates for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.